HAEMONETICS

MU:HAZ Germany Other
Market Cap
$490.47K
€477.82K EUR
Market Cap Rank
#37439 Global
#4825 in Germany
Share Price
€52.60
Change (1 day)
-3.38%
52-Week Range
€41.40 - €73.50
All Time High
€125.20
About

HAEMONETICS operates in Diversified Metals & Mining.

HAEMONETICS (HAZ) - Net Assets

Latest net assets as of September 2024: €878.85 Million EUR

Based on the latest financial reports, HAEMONETICS (HAZ) has net assets worth €878.85 Million EUR as of September 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.53 Billion) and total liabilities (€1.65 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €878.85 Million
% of Total Assets 34.8%
Annual Growth Rate 3.8%
5-Year Change 63.51%
10-Year Change N/A
Growth Volatility 12.69

HAEMONETICS - Net Assets Trend (2017–2024)

This chart illustrates how HAEMONETICS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for HAEMONETICS (2017–2024)

The table below shows the annual net assets of HAEMONETICS from 2017 to 2024.

Year Net Assets Change
2024-03-31 €959.96 Million +17.35%
2023-03-31 €818.00 Million +9.15%
2022-03-31 €749.42 Million +2.43%
2021-03-31 €731.67 Million +24.62%
2020-03-31 €587.11 Million -12.09%
2019-03-31 €667.87 Million -11.24%
2018-03-31 €752.43 Million +1.73%
2017-03-31 €739.61 Million --

Equity Component Analysis

This analysis shows how different components contribute to HAEMONETICS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 24.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2024)

Component Amount Percentage
Retained Earnings €360.46 Million 37.55%
Other Components €599.50 Million 62.45%
Total Equity €959.96 Million 100.00%

HAEMONETICS Competitors by Market Cap

The table below lists competitors of HAEMONETICS ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in HAEMONETICS's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 817,997,000 to 959,959,000, a change of 141,962,000 (17.4%).
  • Net income of 117,558,000 contributed positively to equity growth.
  • Other factors increased equity by 24,404,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €117.56 Million +12.25%
Other Changes €24.40 Million +2.54%
Total Change €- 17.35%

Book Value vs Market Value Analysis

This analysis compares HAEMONETICS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.78x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 3.72x to 2.78x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-03-31 €14.15 €52.60 x
2018-03-31 €14.37 €52.60 x
2019-03-31 €13.09 €52.60 x
2020-03-31 €11.67 €52.60 x
2021-03-31 €14.38 €52.60 x
2022-03-31 €14.66 €52.60 x
2023-03-31 €16.21 €52.60 x
2024-03-31 €18.90 €52.60 x

Capital Efficiency Dashboard

This dashboard shows how efficiently HAEMONETICS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 12.25%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 8.98%
  • • Asset Turnover: 0.60x
  • • Equity Multiplier: 2.29x
  • Recent ROE (12.25%) is above the historical average (8.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 -3.55% -2.96% 0.72x 1.67x €-100.23 Million
2018 6.06% 5.04% 0.73x 1.64x €-29.67 Million
2019 8.24% 5.69% 0.76x 1.91x €-11.77 Million
2020 13.03% 7.74% 0.78x 2.16x €17.82 Million
2021 10.86% 9.13% 0.48x 2.49x €6.30 Million
2022 5.79% 4.37% 0.53x 2.48x €-31.57 Million
2023 14.11% 9.87% 0.60x 2.37x €33.60 Million
2024 12.25% 8.98% 0.60x 2.29x €21.56 Million

Industry Comparison

This section compares HAEMONETICS's net assets metrics with peer companies in the Other industry.

Industry Context

  • Industry: Other
  • Average net assets among peers: $114,212,818,724
  • Average return on equity (ROE) among peers: -9.08%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
HAEMONETICS (HAZ) €878.85 Million -3.55% 1.87x $516.82K
HORIBA (01H) $204.49 Billion 10.42% 0.82x $989.01K
Tokyu Corporation (01T) $779.37 Billion 3.34% 2.35x $99.73K
GUANGZHOU AUTO -H- (02G) $122.28 Billion 6.59% 0.55x $4.05K
MOSAIC (02M) $10.60 Billion 4.43% 0.90x $280.83K
MOSAIC (02M.SG) (02M) $9.56 Billion 10.46% 0.82x $247.21K
CHINA JO-JO DRGSTRS (04CN.SG) (04CN) $16.67 Million -126.83% 4.46x $1.55 Million
KRAKATAU STEEL -B- (07K) $552.59 Million 3.52% 4.72x $166.99
CN MODERN DAIRY (07M) $7.12 Billion -10.42% 1.50x $1.68K
TOURMALINE OIL (08T) $7.22 Billion 4.81% 0.41x $381.02K
ASIA CASSAVA RESOUR (0ACS) $913.15 Million 2.86% 1.55x $325.03